Biotechnology
News Category
GeoVax Reports Q2 2026 Financial Results and Progress on GEO-MVA Pivotal Study
GeoVax advances its GEO-MVA vaccine toward a pivotal immunobridging study under an expedited EMA pathway, while reporting a net loss of $4.4 million f...
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration
VERAXA Biotech (VRXA) announced the advancement of its bispecific antibody-drug conjugate program VXA-222 after OmniAb completed discovery work, movin...
Quantum BioPharma Outlines Lucid-MS Development Strategy and Commercial Growth Plans in BioMedWire Podcast
Quantum BioPharma’s executive discusses advancing Lucid-MS for multiple sclerosis into Phase 2 trials and the commercial potential of unbuzzd, highlig...
Onco-Innovations Advances Lead Oncology Candidate ONC010 Toward Clinical Studies
Onco-Innovations is progressing its lead PNKP inhibitor ONC010 through manufacturing scale-up, formulation optimization, and clinical planning, aiming...
Tonix Pharmaceuticals Schedules Second-Quarter 2026 Results Call for Aug. 10
Tonix Pharmaceuticals will report Q2 2026 financial results and operational highlights on Aug. 10, 2026, followed by a conference call to discuss rece...
VERAXA Biotech Advances Bispecific ADC Program Under OmniAb Collaboration, Reaching Key Milestone for VXA-222
VERAXA Biotech announced that its bispecific antibody-drug conjugate program VXA-222 has reached a key technical milestone under its collaboration wit...
Onco-Innovations Integrates PNKP Inhibition, Nanoparticle Delivery, and AI to Overcome Key Challenges in Cancer Drug Development
Onco-Innovations is advancing ONC010, a PNKP inhibitor delivered via nanoparticles and supported by AI, to address drug resistance, high clinical tria...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech appoints Christoph Erkel, Ph.D., as chief scientific officer to lead development of its BiTAC platform for cancer therapies targeting s...
VERAXA Biotech Gains Regulatory Support for BiTAC®-TCE Development from Germany's Paul-Ehrlich-Institute
VERAXA Biotech's receipt of Scientific Advice from Germany's Paul-Ehrlich-Institute provides early regulatory guidance for its lead BiTAC®-TCE program...
Onco-Innovations Advances Precision Oncology with ONC010 as Biomarker-Driven Cancer Gains Momentum
Onco-Innovations is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor for biomarker-selected cancers, aligning with the shift toward preci...
Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
Lantern Pharma announced a U.S. patent allowance for methods using a three-gene biomarker signature to select and treat patients with ovarian, primary...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG appointed Christoph Erkel, Ph.D., as chief scientific officer to lead development of its proprietary BiTAC platform technologies for...
iOrganBio Appoints Lee L. Rubin, Ph.D., to Scientific Advisory Board, Enhancing Neurological Expertise
iOrganBio adds leading stem cell biologist Lee L. Rubin to its Scientific Advisory Board, aiming to leverage his expertise in neurodegenerative diseas...
BioAdaptives Completes Manufacturing Readiness for Wellness Product Launch
BioAdaptives has finished commercial manufacturing and logistics setup, positioning it to launch its MyndSystem and Xcellara wellness platforms next m...
Creative Biolabs Expands Microfluidics Platform to Accelerate Antibody Discovery
Creative Biolabs has integrated advanced microfluidic technologies to offer a high-throughput, scalable platform for antibody discovery and immune che...
Quantum BioPharma Pioneers Dual Strategy Against Neurological Disorders with Lucid-MS and unbuzzd
Quantum BioPharma is advancing a two-pronged approach to tackle multiple sclerosis and alcohol intoxication effects, with Lucid-MS targeting MS throug...
Oncotelic Therapeutics Publishes Preclinical Data Supporting Intravenous Everolimus Formulation Sapu003
Oncotelic Therapeutics announced the publication of preclinical data for its intravenous everolimus formulation Sapu003, which aims to overcome pharma...
Kairos Pharma Collaborates With Bayer to Evaluate Combination Therapy for Advanced Prostate Cancer
Kairos Pharma partners with Bayer to test its antibody ENV-105 in combination with XOFIGO for metastatic castration-resistant prostate cancer, potenti...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC-TCE Development
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting its development strategy for the lead BiTAC-TCE prog...
VivoSim Labs Raises $4 Million in Private Placement to Fund Working Capital
VivoSim Labs secured $4 million from a healthcare-focused investor through a private placement of common stock and warrants, with proceeds earmarked f...
Greenwich LifeSciences Provides Update on Phase 3 FLAMINGO-01 Trial for Breast Cancer Immunotherapy
Greenwich LifeSciences announced DSB recommendation to continue its Phase 3 trial without modification and plans to expand enrollment to up to 2,000 p...
Quantum BioPharma Develops Two-Pronged Strategy to Address Unmet Neurological Needs in MS and Alcohol Intoxication
Quantum BioPharma Ltd. is advancing Lucid-MS for multiple sclerosis and unbuzzd for alcohol intoxication, targeting millions affected by these neurolo...
American Fusion Receives Texas Certificate of Registration for Texatron Fusion Engine Testing
American Fusion Inc. secured a Texas Certificate of Registration for industrial radiation machines, enabling R&D on its Texatron Fusion Engine systems...
WHO-Commissioned Study Finds No Evidence Mobile Phones Cause Brain Cancer
A comprehensive review commissioned by the World Health Organization found no link between mobile phone use and brain cancer, potentially easing long-...
Quantum BioPharma Hits Key Study Milestone as Early MS Imaging Data Shows Promising Signal
Quantum BioPharma's imaging study for multiple sclerosis reaches halfway in patient enrollment with encouraging preliminary data, potentially advancin...
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
GeoVax's GEO-MVA vaccine platform aligns with the HHS/ASPR's new five-year strategy emphasizing domestic manufacturing, platform technologies, and pan...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform from Germany’s Paul-Ehrlich-Institute
VERAXA Biotech (NASDAQ: VRXA) has received Scientific Advice from Germany’s Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on th...
VERAXA Biotech Receives Favorable Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on developme...
Regentis Biomaterials Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Regentis Biomaterials announced a Japan patent allowance for its proprietary manufacturing process and formulation for GelrinC, a regenerative knee ca...
MindBio Therapeutics Advances Voice-Based AI Tech for Real-Time Impairment Detection
MindBio Therapeutics is developing an AI-powered voice analysis platform to detect drug and alcohol impairment from short speech samples, offering a n...
Gut Microbial Metabolites Linked to Improved Cancer Immunotherapy Response
A study identifies gut bacteria metabolites that enhance cancer immunotherapy sensitivity, offering potential for new treatments.
SS Innovations Appoints New CFO as Global Expansion and FDA Clearance Efforts Accelerate
SS Innovations International has appointed Sarah M. Romano as CFO, bringing extensive medtech finance experience as the company pursues FDA clearance ...
Creative Biolabs Integrates Microfluidics and Electrochemical Biosensors to Accelerate Next-Generation POCT Diagnostics
Creative Biolabs expands its platform by integrating microfluidics and electrochemical biosensors to address challenges in point-of-care testing, enab...
BioAdaptives Details Xcellara Platform Strategy Ahead of XcellaraHeart Launch
BioAdaptives outlines the scientific strategy behind its Xcellara cellular wellness platform, which combines a clinically proven stem cell mobilizatio...
NeuroOne Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial
NeuroOne Medical Technologies announced a collaboration with Mayo Clinic, funded by the Children's Cancer Research Fund, to evaluate a novel treatment...
Oncotelic Therapeutics Launches AI-Powered GMP Manufacturing Platform to Support Biotech Industry
Oncotelic Therapeutics has introduced an AI-driven manufacturing platform combining its proprietary PDAOAI architecture with robotics from TechForce R...
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS to Phase 2 Trials
Quantum BioPharma reported positive Phase 1 safety data for its first-in-class multiple sclerosis therapy LUCID-MS and submitted an IND to the FDA, pa...
VERAXA Biotech's AI Collaboration Could Amplify Impact of Machine Learning on Cancer Drug Development
VERAXA Biotech's partnership with Ardigen to integrate AI into its BiTAC oncology platform positions it to capitalize on the growing role of artificia...
Tonix Pharmaceuticals Publishes Mpox Research Supporting TNX-801 Vaccine Development
New preclinical research shows a current mpox strain is up to 100,000 times less virulent than historic strains, providing critical insights for vacci...
Nuvectis Pharma Prices $100 Million Public Offering to Advance Pipeline Programs
Nuvectis Pharma announced the pricing of a $100 million public offering to fund development of its NXP100, NXP200, and NXP900 programs, highlighting i...
Kairos Pharma Reports Favorable Interim Phase 1 Safety Data for ENV-105 in EGFR-Mutated Lung Cancer
Kairos Pharma announced favorable interim safety results from its Phase 1 trial of ENV-105 combined with osimertinib for advanced EGFR-mutated NSCLC, ...
NeuroThera Labs Initiates Phase IIb Trial for Tourette Syndrome Treatment at Hannover Medical School
NeuroThera Labs has started its Phase IIb clinical trial of SCI-110, a cannabinoid-based treatment for Tourette Syndrome, at Hannover Medical School i...
Earth Science Tech Capitalizes on Telehealth and Peptide Therapy Growth to Strengthen Market Position
Earth Science Tech (ETST) is leveraging its proprietary technology and strategic subsidiaries to capture a share of the booming telehealth and peptide...
Formycon and OneSource Specialty Pharma Forge Strategic Manufacturing Partnership for Biosimilars
Formycon AG and OneSource Specialty Pharma have announced a strategic partnership to leverage OneSource's manufacturing capabilities for cost-efficien...
Quantum BioPharma Advances Multiple Sclerosis Therapy LUCID-MS into Phase 2 Trials
Quantum BioPharma's LUCID-MS, a neuroprotective therapy targeting myelin restoration, has shown favorable safety in Phase 1 studies and is progressing...
Quantum BioPharma Advances LUCID-MS Toward Phase 2 Trial for Multiple Sclerosis
Quantum BioPharma’s LUCID-MS, a potentially first-in-class therapy targeting myelin loss in multiple sclerosis, shows favorable Phase 1 safety and mov...
Silo Pharma Subsidiary QwikAgents Accepted into AMD AI Developer Program
Silo Pharma's subsidiary QwikAgents has been accepted into AMD's AI Developer Program, gaining access to development tools and cloud credits to advanc...
VERAXA Biotech Leverages AI to Accelerate Cancer Therapy Development
VERAXA Biotech's collaboration with AI firm Ardigen could enhance its BiTAC platform by using AI to identify safer and more effective dual-target comb...